Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2022-01, Vol.33 (1), p.107-108 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 108 |
|---|---|
| container_issue | 1 |
| container_start_page | 107 |
| container_title | Annals of oncology |
| container_volume | 33 |
| creator | Nelli, F. Fabbri, A. Onorato, A. Giannarelli, D. Silvestri, M.A. Giron Berrios, J.R. Virtuoso, A. Marrucci, E. Signorelli, C. Chilelli, M.G. Primi, F. Schirripa, M. Mazzotta, M. Ruggeri, E.M. |
| description | |
| doi_str_mv | 10.1016/j.annonc.2021.09.009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8452134</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753421044884</els_id><sourcerecordid>2576649158</sourcerecordid><originalsourceid>FETCH-LOGICAL-c529t-c86c0f36342ad84f69138cf4dd277d1502e86351b77377a40b6482707c6208033</originalsourceid><addsrcrecordid>eNp9UU1v1DAQjRCILoV_gJCPXJL6K07MAaldSqlUdSVUerUcZ9J6ldiL7UTsH-J34mpLgQu-jOSZN2_ee0XxluCKYCJOtpV2zjtTUUxJhWWFsXxWrEgtZNliTp4XKywpK5ua8aPiVYxbjLGQVL4sjhiv88N0Vfw8HwYwKSI_IG2SXQAZ7QwElALoNIFLyDsU9QBpj7TrkZ2m2fk7cNbY_JVx683t5aeSSDR9vT4tz65viKAdRYs2xjr4gHYBRjtZp8MeBYjzmOmG4CeU7iE3fdzBgdl3EcKik_VOj-hW_yg3mTrN_f518WLQY4Q3j_W4-Pb5_Gb9pbzaXFyuT69KU1OZStMKgwcmGKe6b_kgJGGtGXjf06bpSVYMrWA16ZqGNY3muBO8pQ1ujKC4xYwdFx8Pe3dzN0FvsvygR7ULdsrXK6-t-rfj7L2684tqeU0J43nB-8cFwX-fISY12WhgHLUDP0dF60YILknd5lF-GDXZghhgeKIhWD1ErLbqELF6iFhhqXLEGfbu7xOfQL8z_aMBslGLhaCisZAz7W3IRqve2_8z_AKc4buF</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2576649158</pqid></control><display><type>article</type><title>Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Nelli, F. ; Fabbri, A. ; Onorato, A. ; Giannarelli, D. ; Silvestri, M.A. ; Giron Berrios, J.R. ; Virtuoso, A. ; Marrucci, E. ; Signorelli, C. ; Chilelli, M.G. ; Primi, F. ; Schirripa, M. ; Mazzotta, M. ; Ruggeri, E.M.</creator><creatorcontrib>Nelli, F. ; Fabbri, A. ; Onorato, A. ; Giannarelli, D. ; Silvestri, M.A. ; Giron Berrios, J.R. ; Virtuoso, A. ; Marrucci, E. ; Signorelli, C. ; Chilelli, M.G. ; Primi, F. ; Schirripa, M. ; Mazzotta, M. ; Ruggeri, E.M.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1016/j.annonc.2021.09.009</identifier><identifier>PMID: 34555502</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>BNT162 Vaccine ; COVID-19 ; Humans ; Letter to the Editor ; Neoplasms - drug therapy ; Prospective Studies ; RNA, Messenger ; SARS-CoV-2</subject><ispartof>Annals of oncology, 2022-01, Vol.33 (1), p.107-108</ispartof><rights>2021 European Society for Medical Oncology</rights><rights>2021 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. 2021 European Society for Medical Oncology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c529t-c86c0f36342ad84f69138cf4dd277d1502e86351b77377a40b6482707c6208033</citedby><cites>FETCH-LOGICAL-c529t-c86c0f36342ad84f69138cf4dd277d1502e86351b77377a40b6482707c6208033</cites><orcidid>0000-0001-8374-1362</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34555502$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nelli, F.</creatorcontrib><creatorcontrib>Fabbri, A.</creatorcontrib><creatorcontrib>Onorato, A.</creatorcontrib><creatorcontrib>Giannarelli, D.</creatorcontrib><creatorcontrib>Silvestri, M.A.</creatorcontrib><creatorcontrib>Giron Berrios, J.R.</creatorcontrib><creatorcontrib>Virtuoso, A.</creatorcontrib><creatorcontrib>Marrucci, E.</creatorcontrib><creatorcontrib>Signorelli, C.</creatorcontrib><creatorcontrib>Chilelli, M.G.</creatorcontrib><creatorcontrib>Primi, F.</creatorcontrib><creatorcontrib>Schirripa, M.</creatorcontrib><creatorcontrib>Mazzotta, M.</creatorcontrib><creatorcontrib>Ruggeri, E.M.</creatorcontrib><title>Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><subject>BNT162 Vaccine</subject><subject>COVID-19</subject><subject>Humans</subject><subject>Letter to the Editor</subject><subject>Neoplasms - drug therapy</subject><subject>Prospective Studies</subject><subject>RNA, Messenger</subject><subject>SARS-CoV-2</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UU1v1DAQjRCILoV_gJCPXJL6K07MAaldSqlUdSVUerUcZ9J6ldiL7UTsH-J34mpLgQu-jOSZN2_ee0XxluCKYCJOtpV2zjtTUUxJhWWFsXxWrEgtZNliTp4XKywpK5ua8aPiVYxbjLGQVL4sjhiv88N0Vfw8HwYwKSI_IG2SXQAZ7QwElALoNIFLyDsU9QBpj7TrkZ2m2fk7cNbY_JVx683t5aeSSDR9vT4tz65viKAdRYs2xjr4gHYBRjtZp8MeBYjzmOmG4CeU7iE3fdzBgdl3EcKik_VOj-hW_yg3mTrN_f518WLQY4Q3j_W4-Pb5_Gb9pbzaXFyuT69KU1OZStMKgwcmGKe6b_kgJGGtGXjf06bpSVYMrWA16ZqGNY3muBO8pQ1ujKC4xYwdFx8Pe3dzN0FvsvygR7ULdsrXK6-t-rfj7L2684tqeU0J43nB-8cFwX-fISY12WhgHLUDP0dF60YILknd5lF-GDXZghhgeKIhWD1ErLbqELF6iFhhqXLEGfbu7xOfQL8z_aMBslGLhaCisZAz7W3IRqve2_8z_AKc4buF</recordid><startdate>20220101</startdate><enddate>20220101</enddate><creator>Nelli, F.</creator><creator>Fabbri, A.</creator><creator>Onorato, A.</creator><creator>Giannarelli, D.</creator><creator>Silvestri, M.A.</creator><creator>Giron Berrios, J.R.</creator><creator>Virtuoso, A.</creator><creator>Marrucci, E.</creator><creator>Signorelli, C.</creator><creator>Chilelli, M.G.</creator><creator>Primi, F.</creator><creator>Schirripa, M.</creator><creator>Mazzotta, M.</creator><creator>Ruggeri, E.M.</creator><general>Elsevier Ltd</general><general>European Society for Medical Oncology. Published by Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8374-1362</orcidid></search><sort><creationdate>20220101</creationdate><title>Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study</title><author>Nelli, F. ; Fabbri, A. ; Onorato, A. ; Giannarelli, D. ; Silvestri, M.A. ; Giron Berrios, J.R. ; Virtuoso, A. ; Marrucci, E. ; Signorelli, C. ; Chilelli, M.G. ; Primi, F. ; Schirripa, M. ; Mazzotta, M. ; Ruggeri, E.M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c529t-c86c0f36342ad84f69138cf4dd277d1502e86351b77377a40b6482707c6208033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>BNT162 Vaccine</topic><topic>COVID-19</topic><topic>Humans</topic><topic>Letter to the Editor</topic><topic>Neoplasms - drug therapy</topic><topic>Prospective Studies</topic><topic>RNA, Messenger</topic><topic>SARS-CoV-2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nelli, F.</creatorcontrib><creatorcontrib>Fabbri, A.</creatorcontrib><creatorcontrib>Onorato, A.</creatorcontrib><creatorcontrib>Giannarelli, D.</creatorcontrib><creatorcontrib>Silvestri, M.A.</creatorcontrib><creatorcontrib>Giron Berrios, J.R.</creatorcontrib><creatorcontrib>Virtuoso, A.</creatorcontrib><creatorcontrib>Marrucci, E.</creatorcontrib><creatorcontrib>Signorelli, C.</creatorcontrib><creatorcontrib>Chilelli, M.G.</creatorcontrib><creatorcontrib>Primi, F.</creatorcontrib><creatorcontrib>Schirripa, M.</creatorcontrib><creatorcontrib>Mazzotta, M.</creatorcontrib><creatorcontrib>Ruggeri, E.M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nelli, F.</au><au>Fabbri, A.</au><au>Onorato, A.</au><au>Giannarelli, D.</au><au>Silvestri, M.A.</au><au>Giron Berrios, J.R.</au><au>Virtuoso, A.</au><au>Marrucci, E.</au><au>Signorelli, C.</au><au>Chilelli, M.G.</au><au>Primi, F.</au><au>Schirripa, M.</au><au>Mazzotta, M.</au><au>Ruggeri, E.M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2022-01-01</date><risdate>2022</risdate><volume>33</volume><issue>1</issue><spage>107</spage><epage>108</epage><pages>107-108</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><cop>England</cop><pub>Elsevier Ltd</pub><pmid>34555502</pmid><doi>10.1016/j.annonc.2021.09.009</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0001-8374-1362</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2022-01, Vol.33 (1), p.107-108 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8452134 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | BNT162 Vaccine COVID-19 Humans Letter to the Editor Neoplasms - drug therapy Prospective Studies RNA, Messenger SARS-CoV-2 |
| title | Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T02%3A30%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20active%20cancer%20treatment%20on%20safety%20and%20immunogenicity%20of%20COVID-19%20mRNA-BNT162b2%20vaccine:%20preliminary%20results%20from%20the%20prospective%20observational%20Vax-On%20study&rft.jtitle=Annals%20of%20oncology&rft.au=Nelli,%20F.&rft.date=2022-01-01&rft.volume=33&rft.issue=1&rft.spage=107&rft.epage=108&rft.pages=107-108&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1016/j.annonc.2021.09.009&rft_dat=%3Cproquest_pubme%3E2576649158%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2576649158&rft_id=info:pmid/34555502&rft_els_id=S0923753421044884&rfr_iscdi=true |